Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Cooperberg

Showing results (21-30 of 522) with videos related to

Pageof 53
Sort By:
Lancet (London, England)|November 8, 2011
High-risk prostate cancer: treat the prostateMatthew R Cooperberg
European Urology|February 8, 2018
How Should a Man with Prostate Cancer Choose his Surgeon?Matthew R Cooperberg
European Urology|April 24, 2013
Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screeningMatthew R Cooperberg
European Urology|November 8, 2016
Re: 10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerMatthew R Cooperberg
European Urology|November 15, 2016
Magnetic Resonance Imaging-targeted Prostate Biopsies: Is the Right Technique the Right Question?Matthew R Cooperberg
Nature Reviews. Clinical Oncology|April 2, 2014
Prostate cancer: a new look at prostate cancer treatment complicationsMatthew R Cooperberg
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 12, 2025
Is uptake of AS in low-risk prostate cancer in Ontario linked to guideline publication?Matthew R Cooperberg
European Urology|January 29, 2023
Active Surveillance in Michigan: What Is Possible When Payers Partner with PhysiciansMatthew R Cooperberg
The Lancet. Oncology|April 3, 2025
PARP inhibitors for prostate cancer: for whom and when?Matthew R Cooperberg
European Urology|July 4, 2012
Will biomarkers save prostate cancer screening?Matthew R Cooperberg
Pageof 53

Showing results (21-30 of 522) with videos related to

Sort By:
Pageof 53
Lancet (London, England)|November 8, 2011
High-risk prostate cancer: treat the prostateMatthew R Cooperberg
European Urology|February 8, 2018
How Should a Man with Prostate Cancer Choose his Surgeon?Matthew R Cooperberg
European Urology|April 24, 2013
Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screeningMatthew R Cooperberg
European Urology|November 8, 2016
Re: 10-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Localized Prostate CancerMatthew R Cooperberg
European Urology|November 15, 2016
Magnetic Resonance Imaging-targeted Prostate Biopsies: Is the Right Technique the Right Question?Matthew R Cooperberg
Nature Reviews. Clinical Oncology|April 2, 2014
Prostate cancer: a new look at prostate cancer treatment complicationsMatthew R Cooperberg
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 12, 2025
Is uptake of AS in low-risk prostate cancer in Ontario linked to guideline publication?Matthew R Cooperberg
European Urology|January 29, 2023
Active Surveillance in Michigan: What Is Possible When Payers Partner with PhysiciansMatthew R Cooperberg
The Lancet. Oncology|April 3, 2025
PARP inhibitors for prostate cancer: for whom and when?Matthew R Cooperberg
European Urology|July 4, 2012
Will biomarkers save prostate cancer screening?Matthew R Cooperberg
Pageof 53